Last reviewed · How we verify
Shenfu Zhusheye
Shenfu Zhusheye, marketed by China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., is a drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the company's strong distribution network and brand recognition. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Shenfu Zhusheye |
|---|---|
| Sponsor | China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction (PHASE4)
- A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Shenfu Zhusheye CI brief — competitive landscape report
- Shenfu Zhusheye updates RSS · CI watch RSS
- China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. portfolio CI